Neurology
Two Neuroscientists Awarded 2026 Ralph L. Sacco Scholarships for Brain Health Research
The American Academy of Neurology and the American Heart Association have awarded $150,000 scholarships to Sarah Kettlety and Cali McEntee to study concussion recovery in children and the effects of exercise on brain aging, respectively.
Oragenics Reports Early Progress in Phase IIa Trial of Intranasal Concussion Therapy
Oragenics Inc. has enrolled two patients and administered eight doses in its Phase IIa trial for ONP-002, a potential first-in-class intranasal treatment for mild traumatic brain injury, addressing a significant unmet medical need in a market with no FDA-approved pharmacological therapies.
Wireless Brain Implants Could Revolutionize Neurological Treatment Without Surgery
MIT researchers have developed microscopic wireless implants that can navigate to brain tissue autonomously, potentially eliminating the need for surgery in treating tumors and neurological conditions.
Study Reveals Neurocognitive Decline in CNS Cancer Patients, Highlighting Treatment Challenges
Recent research demonstrates significant neurocognitive decline in central nervous system cancer patients, emphasizing the critical need for therapies that address both tumor control and cognitive preservation.
NeuroOne Granted 180-Day Extension to Regain Nasdaq Compliance
NeuroOne Medical Technologies has received an additional 180 days to meet Nasdaq's minimum bid price requirement, providing crucial breathing room for the neurological device company to stabilize its stock performance and avoid potential delisting.
Dr. Hos Loftus Earns 2025 Castle Connolly Top Doctor Recognition for Integrated Neurology and Psychology Care
Dr. Hos Loftus has been recognized as a 2025 Castle Connolly Top Doctor for his innovative integrated approach to neurological and psychological care at Carolinas Institute for Neurology and Psychology, highlighting the growing importance of holistic treatment models in modern healthcare.
Study Reveals Chemotherapy May Damage Brain's Waste Drainage System, Explaining 'Chemo Brain' Symptoms
New research identifies chemotherapy-induced damage to the brain's waste drainage network as a potential cause of cognitive difficulties affecting up to 75% of cancer patients during and after treatment.
Lantern Pharma Partners with Hoth Therapeutics to Deploy AI Platform for Blood-Brain Barrier Prediction
Lantern Pharma's AI platform PredictBBB.ai, which boasts 94% accuracy in predicting drug penetration of the blood-brain barrier, is being deployed through a partnership with Hoth Therapeutics to accelerate neurological drug development.
NeuroOne Expands Executive Leadership with Promotion of Emily Johns to Chief Administrative Officer
NeuroOne Medical Technologies has promoted Emily Johns to Chief Administrative Officer, signaling strategic focus on operational infrastructure as the company scales its neurological disorder treatment technologies.
Annovis Bio Secures $6 Million in Registered Direct Offering to Advance Neurodegenerative Disease Therapies
Annovis Bio has closed a $6 million registered direct offering to fund development of treatments for Alzheimer's and Parkinson's diseases, providing crucial capital for advancing late-stage clinical programs targeting neurodegeneration.
Alpha Cognition to Present at Spartan Capital Investor Conference, Highlighting Neurodegenerative Disease Treatments
Alpha Cognition's participation in the Spartan Capital Securities investor conference provides a platform to showcase its innovative treatments for Alzheimer's and cognitive impairment from traumatic brain injury, potentially attracting crucial investment for addressing unmet medical needs.
NeuroOne Expands Global Patent Portfolio with Key Approvals for Neurological Technology
NeuroOne Medical Technologies has strengthened its intellectual property position with new patent approvals in the US and Europe, signaling expanded opportunities for its neurological disorder treatment technologies.
Glioblastoma Found to Erode Skull Tissue, Challenging Long-Held Treatment Assumptions
A recent study reveals that glioblastoma, the deadliest form of brain cancer, erodes patients' skulls, challenging the long-held assumption that the disease is localized and potentially explaining why current therapies have shown dismal success rates.
Annovis Bio Reports Buntanetap Shows Promising Biomarker Improvements in Alzheimer's Patients
Annovis Bio's buntanetap demonstrated significant reductions in inflammatory biomarkers and improved neuronal health markers in Alzheimer's patients, suggesting potential disease-modifying effects for neurodegenerative conditions.
Quantum BioPharma Pioneers Digitally Integrated Biotech Model with Neuroprotective MS Treatment
Quantum BioPharma is transforming biotechnology through a digitally engineered approach that combines clinical innovation with consumer health commercialization and modern market infrastructure.
Oragenics Partners with Receptor.AI to Accelerate AI-Driven Discovery of Brain-Targeted Therapeutics
Oragenics Inc. has formed a strategic collaboration with Receptor.AI to leverage artificial intelligence for developing neurological therapeutics, marking a significant expansion beyond its concussion treatment program.
NeuroOne Reports 163% Revenue Growth Driven by Epilepsy Treatment Technology
NeuroOne Medical Technologies announced record preliminary product revenue of $9.1 million for fiscal 2025, representing 163% growth driven by increased adoption of its OneRF Ablation system for epilepsy treatment.
Quantum BioPharma Advances Multiple Sclerosis Treatment Toward Clinical Trials
Quantum BioPharma has received final toxicity reports for its Lucid-MS drug candidate, clearing a critical regulatory hurdle toward Phase 2 clinical trials for treating multiple sclerosis by targeting demyelination.
Lantern Pharma's AI Platform Helps Hoth Therapeutics Accelerate Drug Development
Hoth Therapeutics is using Lantern Pharma's PredictBBB.ai platform to streamline drug candidate selection by predicting blood-brain barrier penetration with 94% accuracy, potentially accelerating development of neurological treatments.
Quantum BioPharma Appoints Leading MS Expert Dr. Jack Antel as Clinical Advisor for Lucid-MS Development
Quantum BioPharma has strengthened its multiple sclerosis program by appointing renowned neurologist Dr. Jack Antel to guide the clinical development of Lucid-21-302 as the investigational drug advances toward Phase 2 trials.
NeuroOne to Host Investor Webinar Following Recent FDA Clearance
NeuroOne Medical Technologies will hold a virtual investor webinar on October 7, 2025, to discuss business operations and recent FDA clearance, highlighting the company's progress in developing neurological disorder treatments.
New Research Reveals Menopause's Significant Impact on Multiple Sclerosis Symptoms and Comorbidities
Groundbreaking research presented at the ECTRIMS 2025 conference demonstrates how hormonal changes during menopause influence both initial symptoms and comorbidities in women with multiple sclerosis, potentially guiding future treatment development.
Menstrual Migraine Crisis Demands New Treatment Approaches as Health Tech Offers Hope
Millions of women suffer from debilitating menstrual migraines that require specialized hormonal-based treatments and benefit from emerging health technology solutions for better management.
Clene's CNM-Au8 Shows Promising Brain Energy Improvements in Multiple Sclerosis Patients
Clene Inc. presented positive trial results demonstrating that its investigational therapy CNM-Au8 significantly improved brain energy metabolism in multiple sclerosis patients, potentially offering a new approach to slowing disease progression by addressing underlying bioenergetic failure.
Creative Biolabs Launches Advanced Antibody Tools for Neuroscience Research
Creative Biolabs has developed specialized antibody products targeting key neurological proteins that could accelerate research into neurodegenerative diseases, movement disorders, and synaptic function.
Clene's CNM-Au8 Shows Promise in Addressing Cellular Dysfunction in Parkinson's Disease
Clene Inc.'s investigational therapy CNM-Au8 demonstrates potential to improve mitochondrial health and reduce inflammation in Parkinson's disease models, offering new hope for addressing the underlying cellular mechanisms driving neurodegeneration.
UCLA Smart Pen Achieves 96% Accuracy in Early Parkinson's Detection
A UCLA-developed smart pen demonstrates 96.22% efficacy in detecting Parkinson's disease during early stages, potentially revolutionizing diagnosis and treatment effectiveness.
Neuroscience Breakthrough Offers New Hope for Locked-In Syndrome Patients and Consciousness Research
Dr. Berenika Maciejewicz's research provides a new diagnostic framework for detecting consciousness in locked-in syndrome patients, with significant implications for brain-computer interfaces and neurological care.
Clene Inc. Advances Toward NDA Submission for ALS Therapy CNM-Au8®
Clene Inc. is progressing toward submitting a New Drug Application for its ALS treatment CNM-Au8® by late 2025, potentially offering new hope for patients with this devastating neurodegenerative disease.
MadSci Secures $10 Million Oversubscribed Seed Funding for Hydrocephalus Innovation
MedTech startup MadSci's oversubscribed $10 million seed round signals strong investor confidence in its SmartShunt System, which aims to address decades of unmet needs in hydrocephalus treatment through integrated diagnostic and therapeutic technology.